Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: $ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acadia Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acadia Pharmaceuticals's position in the market.
Acadia Pharmaceuticals (ACAD) announced its participation in three upcoming investor conferences in May 2024, aiming to engage with the investment community. The company will host fireside chats at each conference, providing insights into its innovative work in neuroscience. Acadia has a strong track record with FDA-approved drugs for Parkinson's disease psychosis and Rett syndrome, while also focusing on developing treatments for Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric disorders.
Acadia Pharmaceuticals reported strong financial results for the first quarter of 2024, with net product sales reaching $205.8 million, a 74% year-over-year revenue growth. The increase was primarily driven by the addition of DAYBUE for Rett syndrome treatment and growth in NUPLAZID market share for Parkinson's disease psychosis. The company is focusing on expanding DAYBUE globally, advancing late-stage trials, and supporting its pipeline and business development opportunities. Acadia also presented positive clinical trial results and appointed a new executive to lead Research and Development.
Acadia Pharmaceuticals announced the winners of the first Rett Sibling Scholarship, awarding 10 academic scholarships to siblings of Rett syndrome patients. Each recipient will receive $5,000 for higher education. The program aims to support siblings' academic goals and recognize their contributions. Recipients from various states plan to study psychology, finance, and medicine. The scholarship is independently administered by ISTS. Acadia's commitment to the Rett syndrome community is highlighted through this initiative.
